Results 31 to 40 of about 631 (89)

Frequency of the most common CYP3A5 polymorphisms in the healthy population of the Republic of Macedonia [PDF]

Makedonsko Farmacevtski Bilten, 2012
The genetic polymorphism affecting the CYP3A5 enzyme is responsible for inter-individual and interethnic variability in the metabolism of CYP3A5 substrates.
Krume Jakovski, Aleksandra Kapedanovska Nestorovska , Nikola Labacevski, Aleksandar J. Dimovski   +3 more
doaj  

Nudix hydrolase 15 deficiency and azathioprine toxicity in a liver transplant recipient: A case report

JPGN Reports, EarlyView.
Abstract Thiopurines, such as azathioprine (AZA), are among the immunosuppressants used to prevent allograft rejection. Thiopurines are metabolized by thiopurine S‐methyltransferase (TPMT) and nudix hydrolase 15 (NUDT15) enzymes, and their functions are highly influenced by genetic variation. We present a 6‐year‐old female with recurrent acute cellular
Jenny Q. Nguyen, Natalie Rodriguez, Kimberly A. Chapman, Matthew A. Deardorff, Keith Z. Hazleton   +4 more
wiley   +1 more source

Frecuencia de los alelos CYP3A5 en pacientes pediátricos con enfermedad renal crónica avanzada y receptores de trasplante renal en un centro de referencia nacional en Lima, Perú

Investigación e Innovación Clínica y Quirúrgica Pediátrica
Objetivo: Determinar la frecuencia de los alelos CYP3A5*1 y CYP3A5*3 en pacientes pediátricos con enfermedad renal crónica avanzada y trasplante renal atendidos en un centro de referencia nacional en Lima, Perú.
Marlene Lourdes Cisneros Mallcco, Joselyne Olga Talledo Rodriguez   +1 more
doaj   +1 more source

Development of a physiologically‐based pharmacokinetic model for Ritonavir characterizing exposure and drug interaction potential at both acute and steady‐state conditions

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 523-539, March 2025.
Abstract Ritonavir (RTV) is a potent CYP3A inhibitor that is widely used as a pharmacokinetic (PK) enhancer to increase exposure to select protease inhibitors. However, as a strong and complex perpetrator of CYP3A interactions, RTV can also enhance the exposure of other co‐administered CYP3A substrates, potentially causing toxicity.
Lien Thi Ngo, Woojin Jung, Tham Thi Bui, Hwi‐yeol Yun, Jung‐woo Chae, Jeremiah D. Momper   +5 more
wiley   +1 more source

Pharmacokinetics and Pharmacogenetics of Apixaban

Рациональная фармакотерапия в кардиологии, 2020
Apixaban is oral anticoagulant, it is widely used in prevention of stroke in non-valvular atrial fibrillation and treatment of deep vein thrombosis and pulmonary embolism. Its main mechanism of action is through reversible inhibition of factor Xa.
A. V. Savinova, M. M. Petrova, N. A. Shnayder, E. N. Bochanova, R. F. Nasyrova   +4 more
doaj   +1 more source

Integrative Analysis of Plasma Proteome and Genome Reveals Novel Drug Targets for Chronic Rhinosinusitis and Nasal Polyps

World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Background Chronic rhinosinusitis (CRS) and nasal polyps (NP) are chronic inflammatory conditions with unsatisfactory treatment outcomes due to frequent recurrence of refractory disease. Identifying new therapeutic targets is essential. Methods We conducted a proteome‐wide Mendelian randomization (MR) analysis by integrating genome‐wide ...
En Zhou, Shi Luo, Yu Xiao, Bin Liu, Xu‐Ping Xiao   +4 more
wiley   +1 more source

CYP3A5 unexpectedly regulates glucose metabolism through the AKT–TXNIP–GLUT1 axis in pancreatic cancer

Genes and Diseases
CYP3A5 is a cytochrome P450 (CYP) enzyme that metabolizes drugs and contributes to drug resistance in cancer. However, it remains unclear whether CYP3A5 directly influences cancer progression.
Ming Shao, Qingfei Pan, Haiyan Tan, Jing Wu, Ha Won Lee, Andrew D. Huber, William C. Wright, Ji-Hoon Cho, Jiyang Yu, Junmin Peng, Taosheng Chen   +10 more
doaj   +1 more source

Pharmacogenomics of dolutegravir: A scoping review of evidence, gaps and clinical implications

British Journal of Clinical Pharmacology, Volume 92, Issue 11, Page 3716-3732, November 2026.
Dolutegravir underpins modern first‐ and second‐line HIV treatment regimens; however, interindividual variability in its disposition and tolerability presents challenges for optimal use. This scoping review mapped current evidence on the pharmacogenomics of dolutegravir, focusing on pharmacokinetics and pharmacodynamics, and methodological limitations ...
Ronald Kiguba, Mishael Ssesanga, Munir Pirmohamed   +2 more
wiley   +1 more source

Personalized tacrolimus dose requirement by CYP3A5 but not ABCB1 or ACE genotyping in both recipient and donor after pediatric liver transplantation. [PDF]

PLoS ONE, 2014
Tacrolimus (TAC) is the backbone of an immunosuppressive drug used in most solid organ transplant recipients. A single nucleotide polymorphism (SNP) at position 6986G>A in CYP3A5 has been notably involved in the pharmacokinetic variability of TAC.
Yi-kuan Chen, Long-zhi Han, Feng Xue, Cong-huan Shen, Jun Lu, Tai-hua Yang, Jian-jun Zhang, Qiang Xia   +7 more
doaj   +1 more source

Advances in New Approach Methodologies at FDA's Division of Applied Regulatory Science

Clinical Pharmacology &Therapeutics, Volume 120, Issue 5, Page 1250-1254, November 2026.
New Approach Methodologies (NAMs) represent a paradigm shift in drug development and regulatory science, offering human‐relevant alternatives to traditional preclinical models. This mini‐review highlights recent advances in NAM development, validation, and regulatory application from FDA's Division of Applied Regulatory Science (DARS).
Ksenia Blinova, Kimberly Chiu, Anik Chaturbedi, Jahan Cooper, Tromondae K. Feaster, Paula L. Hyland, Lidiya Stavitskaya, Wendy W. Wu, Jeffry Florian, Rodney Rouse   +9 more
wiley   +1 more source